Federal Register / Vol. 82, No. 170 / Tuesday, September 5, 2017 / Notices 41971 

Facsimile: (240)-276–5504 Email: 

greenejaime@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

EP Patent 1999277 (Application No. 

07753436.0) filed 19 March 2007, titled 

‘‘Apparatus for biosensor microarrays based 

on carbon nanotube transistors having 

biological probe materials, method for its 

production and method of electronically 

detecting a biological target material’’, 

validated in FR, DE, IE, and GB, HHS 

Reference No.: E–056–2007/0–EP–04; 

Australia Patent 2007227415 (Application 

No. 2007227415) filed 10/16/08, titled 

‘‘Apparatus for microarray binding sensors 

having biological probe materials using 

carbon nanotube transistors’’, HHS Reference 

No.: E–056–2007/0–AU–05; 

Canada Patent 2646465 (Application No. 

2646465) filed 03/19/07, titled ‘‘Apparatus 

for microarray binding sensors having 

biological probe materials using carbon 

nanotube transistors’’, HHS Reference No.: E– 

056–2007/0–CA–06; 

Japan Patent 5048752 (Application No. 

2009–501490) filed 03/19/07, titled 

‘‘Apparatus for microarray binding sensors 

having biological probe materials using 

carbon nanotube transistors’’, HHS Reference 

No.: E–056–2007/0–JP–07; 

EP Patent 2570490 (Application No. 

12160369.0) filed 03/19/07, titled ‘‘Apparatus 

for microarray binding sensors having 

biological probe materials using carbon 

nanotube transistors’’, validated in FR, DE, 

and GB. HHS Reference No.: E–056–2007/0– 

EP–08; 

U.S. Patent 8,017,938 (Application No. 11/ 

723,369), filed 19 March 2007, titled 

‘‘Apparatus for Microarray Binding Sensors 

Having Biological Probe Materials Using 

Carbon Nanotube Transistors’’, HHS Ref. No.: 

E–056–2007/0–US–03; and 

PCT Application No. PCT/US2007/06809, 

filed 19 March 2007, now abandoned, titled 

‘‘Apparatus for Microarray Binding Sensors 

Having Biological Probe Materials Using 

Carbon Nanotube Transistors’’, HHS Ref. No.: 

E–056–2007/0–PCT–02. 

U.S. Provisional Patent Application No. 

60/743,524, filed 17 March 2006, now 

abandoned, titled ‘‘Apparatus for Microarray 

DNA Binding Sensors Using Carbon 

Nanotube Transistors’’, HHS Ref. No.: E–056– 

2007/0–US–01. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to: ‘‘The 

development of an FDA-approved or 

cleared in vitro diagnostic for the 

detection of hematological 

malignancies, wherein nucleic acids 

encoding one or more of the following 

genes are detected: (1) BCR–ABL, (2) 

FLT3, (3) Btk, (4) Alk, (5) Bcl–2, (6) Akt, 

and (7) PI3K.’’ 

This technology discloses a 

microarray apparatus that uses carbon 

nanotubes transistors and electronic 

circuitry to quantitatively measure 

changes in gene expression levels. 

Typically, microarrays are microscope 

glass slides spotted with thousands of 

different genes. The array does not have 

built-in reader, and the detection is 

performed using a fluorescence scanner 

after hybridization with fluorescenttagged target DNA. For simple nucleic 

acid detection, current methods rely 

upon various combinations of 

enzymatic amplification of nucleic acids 

and fluorescent labeling of targets, 

which entail enzymatic manipulation of 

the nucleic acid being tested and 

chemical labeling, respectively. These 

methods are both time consuming and 

afford limited sensitivity. In cases where 

microarray technology is used as a tool 

for monitoring gene expression patterns 

and profiling of micro RNA (miRNA) in 

normal and cancerous tissue, 

quantification of changes has typically 

been optically-based. While this 

technique is highly sensitive, use of 

optical methods impedes progress in 

both system miniaturization and in 

direct interfacing with data collection 

electronics. 

To overcome the limitation of current 

microarray technologies, the inventors 

have developed a highly sensitive 

microarray apparatus that uses carbon 

nanotube transistors for the electronic 

detection of biological probe-target 

binding. The present invention provides 

an apparatus for biological target 

material detection which uses an array 

of carbon nanotube transistors, with 

each being operated as a field effect 

transistor. A single carbon nanotube 

transistor is associated with a distinct 

biological probe material. The current 

versus voltage characteristics or 

transconductance between the source 

and drain electrodes is measured before 

and after a binding event between the 

biological probe and target materials. By 

using a mathematical relationship, the 

exact amount of target binding can be 

extracted. Importantly, the present 

apparatus offers a significant advantage 

in simplicity of protocol as the method 

used therewith does not require 

chemical or enzymatic manipulation of 

the target being detected. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

Complete applications for a license in 

the prospective field of use that are filed 

in response to this notice will be treated 

as objections to the grant of the 

contemplated Exclusive 

Commercialization Patent License 

Agreement. Comments and objections 

submitted to this notice will not be 

made available for public inspection 

and, to the extent permitted by law, will 

not be released under the Freedom of 

Information Act, 5 U.S.C. 552. 

Dated: August 25, 2017. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2017–18668 Filed 9–1–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; 60-Day Comment 

Request; NCI Cancer Genetics 

Services Directory Web-Based 

Application and Update Mailer 

(National Cancer Institute) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995 to provide 

opportunity for public comment on 

proposed data collection projects, the 

National Cancer Institute (NCI) will 

publish periodic summaries of propose 

projects to be submitted to the Office of 

Management and Budget (OMB) for 

review and approval. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 60 days of the date of this 

publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, submit 

comments in writing, or request more 

information on the proposed project, 

contact: Margaret Beckwith, Office of 

Cancer Content, Office of 

Communications and Public Liaison 

(OCPL), 9609 Medical Center Drive, 

Rockville, MD 20892 or call non-tollfree number 240–276–6600 or email 

your request, including your address to: 

nciocpl@mail.nih.gov. Formal requests 

for additional plans and instruments 

must be requested in writing. 

SUPPLEMENTARY INFORMATION: Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 requires: Written 

mstockstill on DSK30JT082PROD with NOTICES

41972 Federal Register / Vol. 82, No. 170 / Tuesday, September 5, 2017 / Notices 

comments and/or suggestions from the 

public and affected agencies are invited 

to address one or more of the following 

points: (1) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

Proposed Collection Title: NCI Cancer 

Genetics Services Directory Web-Based 

Application and Update Mailer, 0925– 

0639, Extension, National Cancer 

Institute (NCI), National Institutes of 

Health (NIH). 

Need and Use of Information 

Collection: The Office of 

Communications and Public Liaison has 

created the NCI Cancer Genetics 

Services Directory on NCI’s Web site 

Cancer.gov. This directory is a 

searchable collection of information 

about professionals who provide 

services related to cancer genetics. 

These services include cancer risk 

assessment, genetic counseling, and 

genetic susceptibility testing. The 

professionals have applied to be in the 

directory using an online application 

form and have met basic criteria 

outlined on the form. 

There are currently 552 genetics 

professionals listed in the directory. 

Approximately 30–60 new professionals 

are added to the directory each year. 

The applicants are nurses, physicians, 

genetic counselors, and other 

professionals who provide services 

related to cancer genetics. The 

information collected on the application 

form includes name, professional 

qualifications, practice locations, and 

the area of specialization. The 

information is updated annually using a 

Web-based update mailer that mirrors 

the application form. 

The NCI Cancer Genetics Services 

Directory is a unique resource for cancer 

patients and their families who are 

looking for information about their 

family risk of cancer and genetic 

counseling. Collecting applicant 

information and verifying it annually by 

using the NCI Cancer Genetics Services 

Directory Web-based Application Form 

and Update Mailer is important for 

providing this information to the public 

and for keeping it current. 

OMB approval is requested for 3 year. 

There are no costs to respondents other 

than their time. The total estimated 

annualized burden hours are 180. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

per response 

(in hours) 

Total annual 

burden Hours 

Web-based Application Form ............ Genetics Professional ...................... 60 1 30/60 30 

Web-based Update Mailer ................ Genetics Professional ...................... 600 1 15/60 150 

Totals .......................................... .......................................................... 660 660 ........................ 180 

Dated: August 21, 2017. 

Karla Bailey, 

Project Clearance Liaison, National Cancer 

Institute, National Institutes of Health. 

[FR Doc. 2017–18667 Filed 9–1–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: Availability for licensing U.S. 

Government owned intellectual 

property for commercial development. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

patent applications listed below may be 

obtained by emailing the indicated 

licensing contact at the National Heart, 

Lung, and Blood, Office of Technology 

Transfer and Development Office of 

Technology Transfer, 31 Center Drive 

Room 4A29, MSC2479, Bethesda, MD 

20892–2479; telephone: 301–402–5579. 

A signed Confidential Disclosure 

Agreement may be required to receive 

copies of the patent applications. 

SUPPLEMENTARY INFORMATION: The 

inventions listed below are owned by an 

agency of the U.S. Government and are 

available for licensing in the U.S. in 

accordance with 35 U.S.C. 209 and 37 

CFR part 404 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. Technology description 

follows. 

Hybrid Computed Tomography 

Scanning System 

Description of Technology: The 

invention relates to a combination 

hybrid computed tomography (CT) 

system that is particularly suited for 

elucidating stages in pulmonary 

diseases, notably cystic fibrosis and 

lung cancer. Improved visualization of 

lung parenchyma and the margins of 

lung cysts and lung nodules (noninvasive ‘‘virtual biopsy’’) may provide 

sufficient detail to distinguish the types 

of cystic lesions and lung nodules such 

that the typical lung tissue pathologic 

biopsy would not be needed to make a 

diagnosis. The system includes placing 

one or more x-ray detector panels near 

the patient’s body initially outside the 

view of a CT scanner and then moved 

into place for a secondary scan. An 

initial low dose scan, CT scan or X-ray, 

can be performed and if a highresolution CT scan is then necessary a 

flat panel detector is positioned near the 

area of interest. It is preferable that the 

flat panel detector be transparent to 

high-energy x-ray photons. The plurality 

of acquired images are then 

reconstructed into a low and highresolution image. 

Potential Commercial Applications: 

• Non-invasive lung biopsies 

Development Stage: 

• Early stage, no prototype. 

Inventors: Han Wen (NHLBI) 

Intellectual Property: HHS Reference 

No. E–175–2017/0–US–01 

• U.S. Provisional Patent Application 

62/546,639 filed August 17, 2017. 

mstockstill on DSK30JT082PROD with NOTICES